180 related articles for article (PubMed ID: 38353948)
1. Prostate Cancer Screening Uptake in Transgender Women.
Kalavacherla S; Riviere P; Kalavacherla S; Anger JT; Murphy JD; Rose BS
JAMA Netw Open; 2024 Feb; 7(2):e2356088. PubMed ID: 38353948
[TBL] [Abstract][Full Text] [Related]
2. Low-Value Prostate-Specific Antigen Screening in Older Males.
Kalavacherla S; Riviere P; Javier-DesLoges J; Banegas MP; McKay RR; Murphy JD; Rose BS
JAMA Netw Open; 2023 Apr; 6(4):e237504. PubMed ID: 37040113
[TBL] [Abstract][Full Text] [Related]
3. Disparities Associated with Shared Decision-making in Prostate Cancer Screening.
Basin MF; Crane K; Basnet A; Chandrasekar T; Shapiro O; Jacob JM; Bratslavsky G; Goldberg H
Eur Urol Focus; 2023 Nov; 9(6):1008-1015. PubMed ID: 37198068
[TBL] [Abstract][Full Text] [Related]
4. Disparities in Prostate Cancer Screening for Transgender Women: An Analysis of the MarketScan Database.
Premo H; Gordee A; Lee HJ; Scales CD; Moul JW; Peterson A
Urology; 2023 Jun; 176():237-242. PubMed ID: 36972765
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
[TBL] [Abstract][Full Text] [Related]
7. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
[TBL] [Abstract][Full Text] [Related]
8. Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes.
Riviere P; Kalavacherla S; Banegas MP; Javier-Desloges J; Martinez ME; Garraway IP; Murphy JD; Rose BS
Cancer; 2023 Jan; 129(1):82-88. PubMed ID: 36345568
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program.
Morley F; Iyer HS; Tamimi RM; Nanus DM; Rebbeck TR; Kensler KH
Cancer Causes Control; 2024 Mar; 35(3):509-521. PubMed ID: 37878135
[TBL] [Abstract][Full Text] [Related]
10. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
Lai SM; Keighley J; Garimella S; Enko M; Parker WP
JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Screening Patterns Among Sexual and Gender Minority Individuals.
Ma SJ; Oladeru OT; Wang K; Attwood K; Singh AK; Haas-Kogan DA; Neira PM
Eur Urol; 2021 May; 79(5):588-592. PubMed ID: 33250303
[TBL] [Abstract][Full Text] [Related]
12. Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
Tang VL; Shi Y; Fung K; Tan J; Espaldon R; Sudore R; Wong ML; Walter LC
JAMA Intern Med; 2016 May; 176(5):654-61. PubMed ID: 27042937
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test.
McCormick ME; Haile ZT
J Cancer Educ; 2023 Aug; 38(4):1313-1321. PubMed ID: 36652189
[TBL] [Abstract][Full Text] [Related]
14. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
[TBL] [Abstract][Full Text] [Related]
15. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
16. Breast and cervical cancer screenings across gender identity: results from the Behavioral Risk Factor Surveillance System before and during the COVID-19 pandemic.
Berzansky I; Reynolds CA; Charlton BM
Cancer Causes Control; 2024 May; 35(5):865-872. PubMed ID: 38280155
[TBL] [Abstract][Full Text] [Related]
17. The State of Prescreening Discussions About Prostate-specific Antigen Testing Following Implementation of the 2012 United States Preventive Services Task Force Statement.
Turini GA; Gjelsvik A; Renzulli JF
Urology; 2017 Jun; 104():122-130. PubMed ID: 28322897
[TBL] [Abstract][Full Text] [Related]
18. HIV Testing Among Transgender Women and Men - 27 States and Guam, 2014-2015.
Pitasi MA; Oraka E; Clark H; Town M; DiNenno EA
MMWR Morb Mortal Wkly Rep; 2017 Aug; 66(33):883-887. PubMed ID: 28837547
[TBL] [Abstract][Full Text] [Related]
19. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.
Kim SP; Karnes RJ; Nguyen PL; Ziegenfuss JY; Thompson RH; Han LC; Shah ND; Smaldone MC; Gross CP; Frank I; Weight CJ; Beebe TJ; Tilburt JC
BJU Int; 2014 May; 113(5b):E106-11. PubMed ID: 24053213
[TBL] [Abstract][Full Text] [Related]
20. National evidence on the use of shared decision making in prostate-specific antigen screening.
Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN
Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
